Rossari Biotech Ltd · NSE:ROSSARI
Rossari Biotech — Q2 FY27 Earnings Presentation
35 slides from Rossari Biotech's earnings presentation, Oct 19, 2026
Slide 1: Exchange filing cover letter for Q2 & H1 FY27 earnings presentation
October 19, 2026 DCS-CRD Listing Compliance BSE Limited National Stock Exchange of India Limited First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Phiroze Jeejeebhoy Towers Plot No. C/1, ‘G’ Block, Bandra- Kurla Complex Dalal Street, Fort Mumbai 400001 Bandra East Mumbai 400051
Slide 2: Rossari Biotech Limited Q2FY27 Investor Presentation
ROSSARI BIOTECH LIMITED Q2FY27 Investor Presentation
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Rossari Biotech Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secu
Slide 4: Q2FY27 Performance Highlights
Q2FY27 Performance Highlights
Slide 5: Management Commentary
Management Commentary Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said We delivered robust consolidated growth of 19% YoY in Q2FY27, achieving a record quarterly revenue of Rs. 698 crores.
Slide 6: Q2FY27 – Key Business Updates
Q2FY27 – Key Business Updates Kingdom of Saudi Arabia (KSA) Facility Home, Personal Care and Performance Chemicals • The Board has approved the leasing of land by Rossari International • Successfully completed the Stage 1 EXCiPACT audit for Pharma business Limited Company, a wholly owned subsidiary,
Slide 7: Key Financial Highlights
Key Financial Highlights Total Revenue Gross Profit (INR in crores) +23% 1,394.8 31.6% 31.6% 31.7% 30.6% Margin 1,129.8 +19% +19% 697.6 426.7 586.1 +19% 357.6 220.3 185.2 Q2FY26 Q2FY27 H1FY26 H1FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 EBITDA Profit After Tax 12.3% 12.5% 12.4% 12.0% 6.3% 5.6% 6.2% 5.3% M
Slide 8: Q2FY27 Operating Performance
Q2FY27 Operating Performance (INR in crores) HPPC – Home, Personal Care and Performance Chemicals TSC - Textile Specialty Chemicals +24% +24% 1,095.1 226.9 +18% 885.3 +26% 183.1 542.0 120.8 458.9 95.8 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 AHN – Animal Health & Nutrition Geo
Slide 9: Performance excluding Institutional and B2C
Performance excluding Institutional and B2C (INR in crores) Revenue EBITDA 14.8% 14.1% 15.3% 13.8% Margin +27% +14% 1,246.2 171.3 150.3 984.4 +21% +15% 619.9 87.2 511.0 75.7 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 • Our core business continued to deliver strong YoY growth, dr
Slide 10: Institutional and B2C Performance
Institutional and B2C Performance (INR in crores) Revenue EBITDA -5.2% 0.2% -7.3% -2.5% Margin +2% 0.2 145.4 148.6 +3% -3.7 -3.9 75.1 77.7 -10.6 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 Q2 FY26 Q2 FY27 H1 FY26 H1 FY27 • Revenue from Institutional & B2C business remained flat on a YoY basis; however, profitab
Slide 11: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (INR in crores) Q2FY27 Q2FY26 YoY% H1FY27 H1FY26 YoY% Revenues from Operations 697.6 586.1 19.0% 1,394.8 1,129.8 23.5% Cost of Goods Sold 477.3 400.9 968.1 772.2 Gross Profit 220.3 185.2 18.9% 426.7 357.6 19.3% Gross Profit Margin (%) 31.6% 31.6% 30.6
Slide 12: Consolidated Balance Sheet
Consolidated Balance Sheet ASSETS (INR in crores) Sep-26 Mar-26 EQUITY & LIABILITIES (INR in crores) Sep-26 Mar-26 Non-current Assets 1,058.8 1,045.1 Equity 1,407.6 1,333.3 Property, plant and equipment 510.7 466.5 Equity Share Capital 11.1 11.1 Right of Use Assets 91.7 94.0 Capital Work-in-progress
Slide 13: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (INR in crores) Sep-26 Sep-25 Net Profit before Tax 96.9 95.8 Adjustments for: Non-Cash Items/ Other Investment or Financial Items 76.1 42.5 Operating Profit before working capital changes 173.0 138.3 Changes in Working Capital -16.1 -132.2 Cash generated
Slide 14: Company Overview
Company Overview
Slide 15: Rossari – A Surfactant and Ethoxylation-led Specialty Chemical Company
Rossari – A Surfactant and Ethoxylation-led Specialty Chemical Company 29+ 4 80+ 8 Manufacturing 387,100 Years of R&D Countries MTPA Experience Centres Served Facilities Capacity FY26 Revenue Rs. 2,396 crores Rossari is a Specialty-Chemical manufacturer Expertise in Ethoxylation (surfactant chemistr
Slide 16: 29+ Years Journey of Transformation
29+ Years Journey of Transformation 1997 – 2004 2006 – 2011 2013 – 2019 • 1997: Founded by Edward • Established a large-scale • Approved its textile auxiliaries’ range • Launched HPPC Division • Supplies to leading washing Menezes and Sunil Chari as a manufacturing facility at Silvassa by the Global
Slide 17: HPPC - Home, Personal Care and Performance Chemicals
HPPC - Home, Personal Care and Performance Chemicals Home Care Soaps & Detergents | Surfactants | Cleaning, Hygiene and Disinfectant 77% FY26 Revenue Preservatives | Aroma and Fine chemicals | Hygiene | Bath & Body | Personal Care Skin & Hair care | Sun Care & Photoprotection Oil & Gas | Agro | Inks
Slide 18: TSC - Textile Specialty Chemicals
TSC - Textile Specialty Chemicals Capturing the entire value chain, offering true ‘Fibre to Fabric’ solutions for Spin Finishes Enhancing textile performance before spinning and weaving 17% FY26 Revenue Silicon based Lubricants Wax infused lubricants for superior thread and yarn quality Technical Te
Slide 19: AHN - Animal Health Nutrition
AHN - Animal Health Nutrition Evolving into highly specialised life sciences platform 6% FY26 Revenue Poultry Nutrition Aquaculture Dairy Nutrition Pet Care 125+ Customers R&D Led Innovation R&D Centre is at the forefront of developing enzymes, probiotics, herbal products, and non- antibiotic al
Slide 20: Key Subsidiaries
Key Subsidiaries Description Acquisition Details / Rationale Revenue (Rs. crores) Incorporated in 1980, a leading supplier of Surfactants, Agreed to acquire 100% equity stake, out of which 80% equity CAGR 19% Emulsifiers and Specialty chemicals stake is acquired till date for a consideration of
Slide 21: Robust Manufacturing Capabilities
Robust Manufacturing Capabilities 8 Manufacturing Facilities 3,87,100 MTPA Installed Capacity 3,000+ Products 4 R&D Centres Dahej Plant (I) 1,52,500 MTPA | ~23 Acres Dahej Plant (II) 90, 000 MTPA | ~22 Acres State-of-the-art facility, well-equipped with advanced Expertise in Ethoxylation, Propox
Slide 22: Expanding Global Footprint
Expanding Global Footprint Strengthening access to new markets, better raw materials availability and deeper customer engagement FY26 Revenue Mix 74% Domestic 26% Export Transitioning from a domestic specialty chemicals manufacturer into a globally integrated solutions provider, expanding horizons a
Slide 23: Strong R&D Capabilities: Rossari GRIC
Strong R&D Capabilities: The Foundation of 3,000+ Product Portfolio Rossari GRIC 45+ 4 70+ Global Research and Innovation Centre Team R&D New Launches Members Centres in FY26 Integrated R&D facility at Navi Mumbai Rossari’s R&D Priorities Sustainable Chemistry Agro and Pharma Applications Replacing
Slide 24: Awards, Certifications & Recognitions
Awards, Certifications & Recognitions Frost and Sullivan Awards 2026 FICCI Special Jury Award - FY24 For Eco-efficient textile chemistry technology innovation For Innovation in Water Technology Golden Peacock Award - FY24 PMFAI Company of the Year – Unitop Chemicals - FY24 For Innovative Product : F
Slide 25: Social Responsibility and Sustainability
Social Responsibility and Sustainability Various initiatives to address key societal priorities through focused interventions in education, healthcare, human life upliftment, & environmental sustainability. Education and Community Empowerment Medical and Healthcare Support Human Life Upliftment and
Slide 26: Experienced Promoters and Board of Directors
Experienced Promoters and Board of Directors Founders and Promoters Independent Directors • Over 27 years of experience in the banking and financial services sector. His journey features extensive leadership and expertise across retail lending, capital • Over 40 years of experience in the specialty
Slide 27: Key Strategies
Key Strategies
Slide 28: Capabilities Built Up For Long-term Growth
Capabilities Built Up For Long-term Growth (in MTPA) 3,87,100 5,000 • Invested patient capital 15,000 15,000 Thailand for long-term value Dahej unlocking 20,000 Dahej 600 15,000 Dahej • Recently invested in Vasai Sarigam 64,000 sectors like Oil & Gas and Pharma 2,52,500 Dahej • Long-gestation opport
Slide 29: Key Growth Strategies
Key Growth Strategies Accelerating growth in Innovation & new product Strengthening Strengthening Building new core business lines development manufacturing footprint international presence growth platforms Deepen customer Strong product Utilise newly Expand international Scale new busines
Slide 30: Historical Financial Highlights
HistoricalQ2FY27 Key Highlights Financial Highlights
Slide 31: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (INR in crores) FY26 FY25 FY24 Revenues from Operations 2,396.4 2,080.3 1,830.6 Cost of Goods Sold 1,668.7 1,433.3 1,293.5 Gross Profit 727.6 647.0 537.1 Gross Profit Margin (%) 30.4% 31.1% 29.3% Employee expense 154.7 132.3 103.1 Other expenses 287.0
Slide 32: Consolidated Balance Sheet
Consolidated Balance Sheet ASSETS (INR in crores) FY26 FY25 FY24 EQUITY & LIABILITIES (INR in crores) FY26 FY25 FY24 Non-current Assets 1,045.1 853.0 727.4 Equity 1,333.3 1,185.4 1,047.7 Property, plant and equipment 466.5 285.2 260.6 Right of Use Assets 94.0 68.4 54.1 Equity Share Capital 11.1 11.1
Slide 33: Key Financial Highlights
Key Financial Highlights (INR in crores) Total Revenue Export as % of Total Revenue 2,396 2,080 139 Export 18% 23% 24% 26% 1,831 116 400 27% 1,656 108 344 1,483 126 354 112 373 405 1,857 Domestic 82% 77% 76% 74% 1,620 73% 1,369 966 1,157 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 HPPC TSC AHN
Slide 34: Consolidated Key Ratios
Consolidated Key Ratios Net Debt to Equity (x) Working Capital Days 97 95 97 76 79 0.22 0.04 0.07 -0.09 -0.09 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 ROCE (%) ROE (%) 24% 16% 21% 21% 13% 17% 12% 12% 12% 15% FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Key Highlights Financial Highligh
Slide 35: Thank You
Thank You Company Investor Relations Advisor Rossari Biotech Limited Strategic Growth Advisors CIN – L24100MH2009PLC194818 CIN - U74140MH2010PTC204285 Mr. Ketan Sablok, Group CFO Mr. Sudarshan Dhekane / Ms. Vaamaa Choksi ketan.sablok@rossari.com +91 91370 13450 / +91 90222 08577 sudarshan.dhekane@sg